the cochrane collaboration
the cochrane collaboration Company Information
Group Structure
View All
Industry
Other human health activities
Registered Address
11-13 cavendish square, london, W1G 0AN
Website
http://cochrane.orgthe cochrane collaboration Estimated Valuation
Pomanda estimates the enterprise value of THE COCHRANE COLLABORATION at £5.8m based on a Turnover of £9.7m and 0.6x industry multiple (adjusted for size and gross margin).
the cochrane collaboration Estimated Valuation
Pomanda estimates the enterprise value of THE COCHRANE COLLABORATION at £0 based on an EBITDA of £-60.4k and a 4.6x industry multiple (adjusted for size and gross margin).
the cochrane collaboration Estimated Valuation
Pomanda estimates the enterprise value of THE COCHRANE COLLABORATION at £23.3m based on Net Assets of £9.9m and 2.35x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
The Cochrane Collaboration Overview
The Cochrane Collaboration is a live company located in london, W1G 0AN with a Companies House number of 03044323. It operates in the other human health activities sector, SIC Code 86900. Founded in April 1995, it's largest shareholder is unknown. The Cochrane Collaboration is a mature, mid sized company, Pomanda has estimated its turnover at £9.7m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
The Cochrane Collaboration Health Check
Pomanda's financial health check has awarded The Cochrane Collaboration a 5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 4 areas for improvement. Company Health Check FAQs
6 Strong
1 Regular
4 Weak
Size
annual sales of £9.7m, make it larger than the average company (£796.3k)
£9.7m - The Cochrane Collaboration
£796.3k - Industry AVG
Growth
3 year (CAGR) sales growth of -9%, show it is growing at a slower rate (6.5%)
-9% - The Cochrane Collaboration
6.5% - Industry AVG
Production
with a gross margin of 36.5%, this company has a comparable cost of product (36.5%)
36.5% - The Cochrane Collaboration
36.5% - Industry AVG
Profitability
an operating margin of -0.6% make it less profitable than the average company (5.5%)
-0.6% - The Cochrane Collaboration
5.5% - Industry AVG
Employees
with 79 employees, this is above the industry average (19)
79 - The Cochrane Collaboration
19 - Industry AVG
Pay Structure
on an average salary of £55.9k, the company has a higher pay structure (£26.9k)
£55.9k - The Cochrane Collaboration
£26.9k - Industry AVG
Efficiency
resulting in sales per employee of £123.3k, this is more efficient (£51.3k)
£123.3k - The Cochrane Collaboration
£51.3k - Industry AVG
Debtor Days
it gets paid by customers after 1 days, this is earlier than average (22 days)
1 days - The Cochrane Collaboration
22 days - Industry AVG
Creditor Days
its suppliers are paid after 12 days, this is quicker than average (17 days)
12 days - The Cochrane Collaboration
17 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - The Cochrane Collaboration
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 397 weeks, this is more cash available to meet short term requirements (102 weeks)
397 weeks - The Cochrane Collaboration
102 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 11.5%, this is a lower level of debt than the average (27.9%)
11.5% - The Cochrane Collaboration
27.9% - Industry AVG
THE COCHRANE COLLABORATION financials
The Cochrane Collaboration's latest turnover from December 2023 is £9.7 million and the company has net assets of £9.9 million. According to their latest financial statements, The Cochrane Collaboration has 79 employees and maintains cash reserves of £9.9 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 9,743,000 | 8,897,000 | 7,692,000 | 12,829,000 | 8,079,000 | 9,795,496 | 8,669,412 | 6,805,399 | 5,433,071 | 3,707,850 | 4,558,815 | 4,022,746 | 3,027,492 | 2,894,585 | 2,532,601 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | |||||||||||||||
| Interest Payable | 3,708 | 2,967 | 2,370 | 2,169 | 1,899 | ||||||||||
| Interest Receivable | |||||||||||||||
| Pre-Tax Profit | 337,000 | 1,012,000 | -1,415,000 | 3,781,000 | -1,027,000 | 1,314,072 | 562,650 | -1,280,263 | -805,593 | 854,561 | 1,186,098 | 1,408,524 | 597,448 | 691,008 | 739,248 |
| Tax | |||||||||||||||
| Profit After Tax | 337,000 | 1,012,000 | -1,415,000 | 3,781,000 | -1,027,000 | 1,314,072 | 562,650 | -1,280,263 | -805,593 | 854,561 | 1,186,098 | 1,408,524 | 597,448 | 691,008 | 739,248 |
| Dividends Paid | |||||||||||||||
| Retained Profit | 337,000 | 1,012,000 | -1,415,000 | 3,781,000 | -1,027,000 | 1,314,072 | 562,650 | -1,280,263 | -805,593 | 854,561 | 1,186,098 | 1,408,524 | 597,448 | 691,008 | 739,248 |
| Employee Costs | 4,418,000 | 3,715,000 | 4,743,000 | 4,342,000 | 3,981,000 | 3,693,264 | 3,459,774 | 3,186,387 | 2,289,139 | 1,210,120 | 1,285,746 | 798,942 | 808,434 | 701,846 | 517,729 |
| Number Of Employees | 79 | 63 | 75 | 73 | 65 | 65 | 64 | 65 | 32 | 30 | 22 | 14 | 15 | 11 | 8 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 1,000 | 2,000 | 2,520 | 9,439 | 19,685 | 22,955 | 7,653 | 14,518 | 14,425 | 13,923 | 17,807 | 15,090 | |||
| Intangible Assets | |||||||||||||||
| Investments & Other | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 |
| Debtors (Due After 1 year) | 200,000 | 721,271 | 721,271 | 721,271 | 721,271 | ||||||||||
| Total Fixed Assets | 1,000 | 1,000 | 1,000 | 2,000 | 3,000 | 3,520 | 10,439 | 220,685 | 745,226 | 729,924 | 736,789 | 736,696 | 14,923 | 18,807 | 16,090 |
| Stock & work in progress | |||||||||||||||
| Trade Debtors | 48,000 | 167,000 | 203,000 | 93,000 | 23,000 | 2,223,748 | 1,170,921 | 2,076,098 | 20,677 | 7,430 | 379 | 35,436 | 23,796 | ||
| Group Debtors | |||||||||||||||
| Misc Debtors | 1,313,000 | 1,197,000 | 752,000 | 1,134,000 | 1,692,000 | 355,535 | 431,534 | 537,967 | 1,396,056 | 1,132,447 | 1,147,517 | 1,087,027 | 1,289,052 | 639,108 | 680,937 |
| Cash | 9,850,000 | 9,567,000 | 9,096,000 | 9,945,000 | 5,797,000 | 5,523,262 | 5,443,877 | 4,339,026 | 6,345,753 | 7,003,035 | 6,672,908 | 5,466,392 | 3,564,035 | 3,294,935 | 2,512,768 |
| misc current assets | |||||||||||||||
| total current assets | 11,211,000 | 10,931,000 | 10,051,000 | 11,172,000 | 7,512,000 | 8,102,545 | 7,046,332 | 6,953,091 | 7,762,486 | 8,142,912 | 7,820,425 | 6,553,798 | 4,888,523 | 3,957,839 | 3,193,705 |
| total assets | 11,212,000 | 10,932,000 | 10,052,000 | 11,174,000 | 7,515,000 | 8,106,065 | 7,056,771 | 7,173,776 | 8,507,712 | 8,872,836 | 8,557,214 | 7,290,494 | 4,903,446 | 3,976,646 | 3,209,795 |
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 204,000 | 379,000 | 362,000 | 171,000 | 132,000 | 102,732 | 226,310 | 557,764 | 277,292 | 164,565 | 197,731 | 150,507 | 99,777 | 136,813 | |
| Group/Directors Accounts | |||||||||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 1,084,000 | 959,000 | 1,109,000 | 991,000 | 1,164,000 | 757,321 | 871,125 | 1,193,795 | 1,072,316 | 544,574 | 900,347 | 666,949 | 689,155 | 322,767 | 383,737 |
| total current liabilities | 1,288,000 | 1,338,000 | 1,471,000 | 1,162,000 | 1,296,000 | 860,053 | 1,097,435 | 1,751,559 | 1,349,608 | 709,139 | 1,098,078 | 817,456 | 788,932 | 459,580 | 383,737 |
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | 400,000 | 600,000 | 750,000 | 950,000 | |||||||||||
| other liabilities | |||||||||||||||
| provisions | |||||||||||||||
| total long term liabilities | 400,000 | 600,000 | 750,000 | 950,000 | |||||||||||
| total liabilities | 1,288,000 | 1,338,000 | 1,471,000 | 1,162,000 | 1,296,000 | 860,053 | 1,097,435 | 1,751,559 | 1,749,608 | 1,309,139 | 1,848,078 | 1,767,456 | 788,932 | 459,580 | 383,737 |
| net assets | 9,924,000 | 9,594,000 | 8,581,000 | 10,012,000 | 6,219,000 | 7,246,012 | 5,959,336 | 5,422,217 | 6,758,104 | 7,563,697 | 6,709,136 | 5,523,038 | 4,114,514 | 3,517,066 | 2,826,058 |
| total shareholders funds | 9,924,000 | 9,594,000 | 8,581,000 | 10,012,000 | 6,219,000 | 7,246,012 | 5,959,336 | 5,422,217 | 6,758,104 | 7,563,697 | 6,709,136 | 5,523,038 | 4,114,514 | 3,517,066 | 2,826,058 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | |||||||||||||||
| Depreciation | 1,000 | 1,000 | 1,000 | 9,312 | 10,386 | 9,393 | 16,618 | 3,816 | 6,755 | 8,707 | 7,418 | 6,417 | 4,364 | ||
| Amortisation | |||||||||||||||
| Tax | |||||||||||||||
| Stock | |||||||||||||||
| Debtors | -3,000 | 409,000 | -272,000 | -488,000 | -864,283 | 976,828 | -1,211,610 | 676,061 | 276,856 | 52,471 | 60,111 | 484,189 | 661,584 | -18,033 | 680,937 |
| Creditors | -175,000 | 17,000 | 191,000 | 39,000 | 29,268 | -123,578 | -331,454 | 280,472 | 112,727 | 14,058 | 47,224 | 50,730 | -37,036 | 136,813 | |
| Accruals and Deferred Income | 125,000 | -150,000 | 118,000 | -173,000 | 406,679 | -113,804 | -322,670 | -278,521 | 327,742 | -472,375 | 33,398 | 927,794 | 366,388 | -60,970 | 383,737 |
| Deferred Taxes & Provisions | |||||||||||||||
| Cash flow from operations | |||||||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | -2,393 | -140 | -6,123 | -31,920 | |||||||||||
| Change in Investments | 1,000 | ||||||||||||||
| cash flow from investments | -2,393 | -140 | -6,123 | -31,920 | |||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | |||||||||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | -3,708 | -2,967 | -2,370 | -2,169 | -1,899 | ||||||||||
| cash flow from financing | -7,000 | 1,000 | -16,000 | 12,000 | -12 | -27,396 | -25,531 | -55,624 | 1,182,390 | -2,967 | -2,370 | -2,169 | -1,899 | 2,086,810 | |
| cash and cash equivalents | |||||||||||||||
| cash | 283,000 | 471,000 | -849,000 | 4,148,000 | 273,738 | 79,385 | 1,104,851 | -2,006,727 | -657,282 | 1,536,643 | 1,206,516 | 1,902,357 | 269,100 | 782,167 | 2,512,768 |
| overdraft | |||||||||||||||
| change in cash | 283,000 | 471,000 | -849,000 | 4,148,000 | 273,738 | 79,385 | 1,104,851 | -2,006,727 | -657,282 | 1,536,643 | 1,206,516 | 1,902,357 | 269,100 | 782,167 | 2,512,768 |
the cochrane collaboration Credit Report and Business Information
The Cochrane Collaboration Competitor Analysis
Perform a competitor analysis for the cochrane collaboration by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other mid companies, companies in W1G area or any other competitors across 12 key performance metrics.
the cochrane collaboration Ownership
THE COCHRANE COLLABORATION group structure
The Cochrane Collaboration has 2 subsidiary companies.
Ultimate parent company
THE COCHRANE COLLABORATION
03044323
2 subsidiaries
the cochrane collaboration directors
The Cochrane Collaboration currently has 10 directors. The longest serving directors include Dr Tamara Kredo (Aug 2020) and Dr Juan Franco (Aug 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Tamara Kredo | South Africa | 50 years | Aug 2020 | - | Director |
| Dr Juan Franco | England | 40 years | Aug 2020 | - | Director |
| Ms Emma Persad | England | 29 years | Nov 2021 | - | Director |
| Professor Gillian Leng | England | 64 years | Oct 2022 | - | Director |
| Dr Wendy Levinson | England | 73 years | Oct 2022 | - | Director |
| Dr Susan Phillips | England | 64 years | Jul 2024 | - | Director |
| Mr Nigel Jones | England | 55 years | Aug 2024 | - | Director |
| Professor Joerg Meerpohl | Germany | 52 years | Nov 2024 | - | Director |
| Dr Giordano Perez Gaxiola | Mexico | 48 years | Nov 2024 | - | Director |
| Professor Vanessa Jordan-Cole | New Zealand | 53 years | Nov 2024 | - | Director |
P&L
December 2023turnover
9.7m
+10%
operating profit
-60.4k
0%
gross margin
36.6%
+0.46%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
9.9m
+0.03%
total assets
11.2m
+0.03%
cash
9.9m
+0.03%
net assets
Total assets minus all liabilities
the cochrane collaboration company details
company number
03044323
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
86900 - Other human health activities
incorporation date
April 1995
age
30
incorporated
UK
ultimate parent company
accounts
Group
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
PRICE BAILEY LLP
address
11-13 cavendish square, london, W1G 0AN
Bank
NATIONAL WESTMINSTER BANK PLC
Legal Advisor
-
the cochrane collaboration Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to the cochrane collaboration.
the cochrane collaboration Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for THE COCHRANE COLLABORATION. This can take several minutes, an email will notify you when this has completed.
the cochrane collaboration Companies House Filings - See Documents
| date | description | view/download |
|---|
